[DOI] [PMC free article] [PubMed] [Google Scholar] 14.Que Q, Guo X, Zhan L, Chen S, Zhang Z, Ni X, Ye B, Wan S
While the long half-life of semaglutide theoretically supports less frequent dosing, clinical data supports either daily oral or weekly injectable schedules
Its certainly not an impossible process to duplicate, but its not a casual synthesis either, and you wouldnt try it without the financial motivations that we see at the moment
No evidence of increase in calcitonin concentrations or development of C-cell Malignancy in response to liraglutide for up to 5 years in the LEADER trial
Chang G, Chen B, Zhang L
Most recently, she served as the executive director diversity & inclusion officer at the Cleveland Clinic